Description

Biocon Ltd. has listed 112,664,585 new equity shares of Rs. 5 each, allotted to QIBs through Qualified Institutional Placement at Rs. 368.35 per share, effective January 20, 2026.

Summary

BSE has approved the listing and trading of 112,664,585 new equity shares of Biocon Ltd. (Scrip Code: 532523, ISIN: INE376G01013) allotted to Qualified Institutional Buyers (QIBs) pursuant to a Qualified Institutional Placement. The shares, with a face value of Rs. 5 each, were issued at Rs. 368.35 per share and will commence trading from January 20, 2026. These new shares rank pari-passu with existing equity shares.

Key Points

  • 112,664,585 new equity shares of Rs. 5 face value each listed
  • Allotted to Qualified Institutional Buyers (QIBs) through QIP route
  • Issue price: Rs. 368.35 per share
  • Distinctive numbers: 1508243189 to 1620907773
  • New shares rank pari-passu with existing equity shares
  • Scrip Code: 532523
  • ISIN: INE376G01013

Regulatory Changes

No regulatory changes. This is a standard listing notification for securities issued through Qualified Institutional Placement.

Compliance Requirements

Trading members must note the listing of these new securities for trading purposes. No specific compliance actions required beyond normal trading procedures for the expanded share capital.

Important Dates

  • Date of Allotment: January 14, 2026
  • Trading Commencement Date: January 20, 2026 (Tuesday)
  • Notice Date: January 19, 2026

Impact Assessment

Market Impact: The listing of over 112 million new shares represents a significant expansion of Biocon’s equity capital through the QIP route. This increases the total outstanding shares and may impact stock liquidity and price dynamics.

Shareholder Impact: Existing shareholders will experience dilution, though the capital raised through QIP at Rs. 368.35 per share provides additional funds to the company for business operations and growth initiatives.

Trading Impact: Increased float may enhance liquidity for institutional and retail investors. The pari-passu ranking ensures equal rights for all equity shareholders.

Impact Justification

Substantial QIP listing of over 112 million shares represents significant equity dilution for Biocon, relevant for existing shareholders and institutional investors tracking equity capital changes.